Search research articles
Contact Us
Filters
Showing results (1-10 of 123) with videos related to
Page
of 13
Sort By:
Recent Patents on Anti-Infective Drug Discovery
|
May 10, 2011
Global clinical trials for the treatment of TB with thioridazine
Martin J Boeree
The New England Journal of Medicine
|
June 2, 2016
Therapy for Tuberculous Meningitis
Martin J Boeree, Stephen H Gillespie, Michael Hoelscher, et al.
The New England Journal of Medicine
|
June 14, 2023
Treatment Strategy for Rifampin-Susceptible Tuberculosis
Martin J Boeree, Norbert Heinrich, Rob E Aarnoutse
American Journal of Respiratory and Critical Care Medicine
|
January 16, 2019
Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
Lindsey H M Te Brake, Martin J Boeree, Robert E Aarnoutse
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
April 25, 2012
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria
Jakko van Ingen, Martin J Boeree, Dick van Soolingen, et al.
Tropical Medicine & International Health : TM & IH
|
March 8, 2011
The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out?
Jossy van den Boogaard, Martin J Boeree, Gibson S Kibiki, et al.
Nature Clinical Practice. Rheumatology
|
November 28, 2008
Mycobacterial disease in patients with rheumatic disease
Jakko van Ingen, Martin J Boeree, P N Richard Dekhuijzen, et al.
Journal of Clinical Microbiology
|
December 28, 2012
Role of rpsA gene sequencing in diagnosis of pyrazinamide resistance
Sami O Simons, Arnout Mulder, Jakko van Ingen, et al.
Expert Review of Anti-Infective Therapy
|
October 16, 2013
Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence
Jakko van Ingen, Beatriz E Ferro, Wouter Hoefsloot, et al.
International Journal of Antimicrobial Agents
|
May 14, 2013
Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance
Jakko van Ingen, Wouter Hoefsloot, Johan W Mouton, et al.
Page
of 13
Search research articles
Search
Showing results (1-10 of 123) with videos related to
Sort By:
Page
of 13
Recent Patents on Anti-Infective Drug Discovery
|
May 10, 2011
Global clinical trials for the treatment of TB with thioridazine
Martin J Boeree
The New England Journal of Medicine
|
June 2, 2016
Therapy for Tuberculous Meningitis
Martin J Boeree, Stephen H Gillespie, Michael Hoelscher, et al.
The New England Journal of Medicine
|
June 14, 2023
Treatment Strategy for Rifampin-Susceptible Tuberculosis
Martin J Boeree, Norbert Heinrich, Rob E Aarnoutse
American Journal of Respiratory and Critical Care Medicine
|
January 16, 2019
Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
Lindsey H M Te Brake, Martin J Boeree, Robert E Aarnoutse
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
April 25, 2012
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria
Jakko van Ingen, Martin J Boeree, Dick van Soolingen, et al.
Tropical Medicine & International Health : TM & IH
|
March 8, 2011
The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out?
Jossy van den Boogaard, Martin J Boeree, Gibson S Kibiki, et al.
Nature Clinical Practice. Rheumatology
|
November 28, 2008
Mycobacterial disease in patients with rheumatic disease
Jakko van Ingen, Martin J Boeree, P N Richard Dekhuijzen, et al.
Journal of Clinical Microbiology
|
December 28, 2012
Role of rpsA gene sequencing in diagnosis of pyrazinamide resistance
Sami O Simons, Arnout Mulder, Jakko van Ingen, et al.
Expert Review of Anti-Infective Therapy
|
October 16, 2013
Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence
Jakko van Ingen, Beatriz E Ferro, Wouter Hoefsloot, et al.
International Journal of Antimicrobial Agents
|
May 14, 2013
Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance
Jakko van Ingen, Wouter Hoefsloot, Johan W Mouton, et al.
Page
of 13